These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27765901)

  • 21. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
    Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
    BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-resistant CXCR4-positive cells have the molecular characteristics of EMT in NSCLC.
    Yin H; Wang Y; Chen W; Zhong S; Liu Z; Zhao J
    Gene; 2016 Dec; 594(1):23-29. PubMed ID: 27581786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2.
    Ye Z; Yin S; Su Z; Bai M; Zhang H; Hei Z; Cai S
    Oncotarget; 2016 Jun; 7(25):37524-37535. PubMed ID: 27229528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2.
    Xu G; Yu H; Shi X; Sun L; Zhou Q; Zheng D; Shi H; Li N; Zhang X; Shao G
    BMC Pulm Med; 2014 Nov; 14():174. PubMed ID: 25380840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.
    Circu M; Cardelli J; Barr MP; O'Byrne K; Mills G; El-Osta H
    PLoS One; 2017; 12(9):e0184922. PubMed ID: 28945807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.
    Zuco V; Cassinelli G; Cossa G; Gatti L; Favini E; Tortoreto M; Cominetti D; Scanziani E; Castiglioni V; Cincinelli R; Giannini G; Zunino F; Zaffaroni N; Lanzi C; Perego P
    Biochem Pharmacol; 2015 Mar; 94(2):79-90. PubMed ID: 25600908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transglutaminase-2 induces N-cadherin expression in TGF-β1-induced epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 2A down-regulation.
    Park MK; You HJ; Lee HJ; Kang JH; Oh SH; Kim SY; Lee CH
    Eur J Cancer; 2013 May; 49(7):1692-705. PubMed ID: 23290789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition.
    Qian YR; Guo Y; Wan HY; Fan L; Feng Y; Ni L; Xiang Y; Li QY
    Oncol Rep; 2013 Jun; 29(6):2408-14. PubMed ID: 23545945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
    Wang ZL; Fan ZQ; Jiang HD; Qu JM
    Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FASN, ErbB2-mediated glycolysis is required for breast cancer cell migration.
    Zhou L; Jiang S; Fu Q; Smith K; Tu K; Li H; Zhao Y
    Oncol Rep; 2016 May; 35(5):2715-22. PubMed ID: 26936618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer.
    Lee SO; Yang X; Duan S; Tsai Y; Strojny LR; Keng P; Chen Y
    Oncotarget; 2016 Feb; 7(6):6626-38. PubMed ID: 26675547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fatty acid synthase mediates the epithelial-mesenchymal transition of breast cancer cells.
    Li J; Dong L; Wei D; Wang X; Zhang S; Li H
    Int J Biol Sci; 2014; 10(2):171-80. PubMed ID: 24520215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells.
    Zhao Z; Zhang L; Yao Q; Tao Z
    Cancer Gene Ther; 2015 Apr; 22(3):108-14. PubMed ID: 25721211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer.
    Shintani Y; Okimura A; Sato K; Nakagiri T; Kadota Y; Inoue M; Sawabata N; Minami M; Ikeda N; Kawahara K; Matsumoto T; Matsuura N; Ohta M; Okumura M
    Ann Thorac Surg; 2011 Nov; 92(5):1794-804; discussion 1804. PubMed ID: 22051275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
    Papaevangelou E; Almeida GS; Box C; deSouza NM; Chung YL
    Int J Cancer; 2018 Aug; 143(4):992-1002. PubMed ID: 29569717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Confluence-dependent resistance to cisplatin in lung cancer cells is regulated by transforming growth factor-beta.
    Yokokura S; Kanaji N; Tadokoro A; Yokokura S; Kadowaki N; Bandoh S
    Exp Lung Res; 2016 May; 42(4):175-81. PubMed ID: 27116015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epicatechin-3-gallate reverses TGF-β1-induced epithelial-to-mesenchymal transition and inhibits cell invasion and protease activities in human lung cancer cells.
    Huang SF; Horng CT; Hsieh YS; Hsieh YH; Chu SC; Chen PN
    Food Chem Toxicol; 2016 Aug; 94():1-10. PubMed ID: 27224248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
    Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
    Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atorvastatin partially inhibits the epithelial-mesenchymal transition in A549 cells induced by TGF-β1 by attenuating the upregulation of SphK1.
    Fan Z; Jiang H; Wang Z; Qu J
    Oncol Rep; 2016 Aug; 36(2):1016-22. PubMed ID: 27349500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.